ProShares Ultra NASDAQ Biotechnology

BIB

Market cap $55M

Overview Fund Activity

56.66 USD

+0.11

0.19%

At close Updated Sep 17, 4:00 PM EDT

1 day

0.19%

5 days

-0.72%

1 month

1.91%

3 months

24.94%

6 months

3.56%

Year to date

10.36%

1 year

-15.76%

5 years

-19.4%

10 years

-33.33%

Financials Banks - Regional

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

2.72% less ownership

Funds ownership: 7.5% [Q1] → 4.77% (-2.72%) [Q2]

22% less funds holding

Funds holding: 23 [Q1] → 18 (-5) [Q2]

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

52% less capital invested

Capital invested by funds: $4.04M [Q1] → $1.92M (-$2.12M) [Q2]

83% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 6

See Fund Rankings

Financial journalist opinion

Investors Business Daily

Donald Trump Is Finally Making Good On Pharma Tariffs Threats, But Stocks Yawn

Trump said late Tuesday his administration will begin implementing pharmaceutical tariffs next month, making good on months of threats.

Donald Trump Is Finally Making Good On Pharma Tariffs Threats, But Stocks Yawn

Investors Business Daily

Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs

President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon."

Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Will The Next Batch Of Tech Earnings Encourage Investors To Rotate Back In?

All eyes will remain on big tech this week with Microsoft, Amazon, Meta, and Apple set to report for Q2. Outlier earnings this week include - McDonald's & Boeing. During this second peak week of the Q2 season, nearly 2,500 companies are set to report.

Will The Next Batch Of Tech Earnings Encourage Investors To Rotate Back In?

Wall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich

Some of the market's favorite biotech stocks have created immense wealth, as in the recent weight-loss drug stock boom. On May 26, Viking Therapeutics (NASDAQ: VKTX ) was trading around $20.25.

3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024

With new innovation, high demand for better treatment, pharmaceutical companies strengthening pipelines and a resurgence of mergers and acquisitions, biotech stocks could offer some of the most explosive opportunities of the year. “What's more, big pharmaceutical companies with sizable piles of cash and the need to address patent expirations on some top-selling products later this decade will be hunting for companies with innovative drugs in development,” says Morningstar.com.

Equity CEFs/ETFs: Top Picks For 2024 - Part II

In Part I of my Top Picks For 2024, I explained why we saw such extreme valuation losses in most equity CEFs in 2023 and what that could-mean for 2024. In my opinion, liquidity was the over-riding factor for why so few stocks, think Magnificent 7, received the lion's share of buy-interest while most everything else suffered, including equity CEFs. But just because the Federal Reserve will continue its Quantitative Tapering doesn't mean that other Fed programs won't increase liquidity in other places.

See News Rankings

Charts implemented using Lightweight Charts™